EMAIL THIS PAGE TO A FRIEND

Molecular genetics and metabolism

Mutant α-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level.


PMID 22841442

Abstract

Recently, plasma globotriaosylsphingosine (lyso-Gb3) has attracted attention as a biomarker of Fabry disease. However, we found a subset of Fabry disease patients who did not show any increase in the plasma lyso-Gb3 concentration, although other patients exhibited apparent enhancement of it. This subset predominantly exhibited the clinical phenotype of later-onset Fabry disease, and gene analysis revealed that the patients harbored the M296I mutation common to Japanese Fabry patients. This amino acid substitution is predicted to cause a small conformational change on the surface of the α-galactosidase A molecule, resulting in residual enzyme activity. Plasma lyso-Gb3 is a good biomarker of Fabry disease but care should be taken when it is used for a definitive diagnosis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G9534
Globotriaosylsphingosine from porcine blood
C36H67NO17